Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study
- Written by PR Newswire
- U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study
- The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022
ADELAIDE, Australia, Nov. 1, 2021 /PRNewswire/ -- Bionomics Limited...
